Combination therapy of phosphate binders and vitamin K

Abstract

A method of treating chronic kidney disease includes administering to a subject in need thereof a combination of a vitamin K and a phosphate binder.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 788,523, filed January 4, 2019, the disclosure of which is incorporated herein by reference in its entirety. technical field [0003] The present disclosure relates to the use of combination therapy comprising a phosphate binder and vitamin K. The combination can be used, for example, to treat patients with chronic kidney disease; to reduce high serum phosphate levels (also known as hyperphosphatemia); to protect the vasculature from calcification; to reverse vascular calcification; To reduce non-bone calcium levels; to alleviate bone degeneration; to reduce the dose of phosphate binders to achieve the same benefit, or to reduce their side effects; and / or to reduce cardiovascular events (MACE), morbidity, or mortality . Background technique [0004] Patients with chronic kidney disease (CKD) are prone to several various complications. For...

AI Technical Summary

Problems solved by technology

Thus, by binding to vitamin K, phosphate binders can further deplete what may already be low (ie, subclinical deficiency) levels of vitamin K in these subjects

Images